Altamira Therapeutics shares are trading higher Thursday after the company announced highlights from its NASAR clinical trial with Bentrio nasal spray were published in video format on the social media channels of the allergology journal, "Allergy."
Companies Reporting Before The Bell
• Delta Air Lines (NYSE:DAL) is projected to report quarterly earnings at $0.35 per share on revenue of $12.55 billion.
Independent peer-reviewed study shows enhanced cell transduction with adeno-associated virus (AAV) vectors, commonly used in gene therapy, when integrating Altamira's peptide-based delivery technology
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.
Altamira Therapeutics Ltd (NASDAQ: CYTO) shares are trading lower by 50% to $0.20 Monday morning after the company recently made strategic moves by partially spinning off its Bentrio business to focus on
U.S. stocks traded mixed this morning, with the Dow Jones index gaining more than 20 points on Monday.
Following the market opening Monday, the Dow traded up 0.07% to 36,272.54 while the NASDAQ fell 0.26% to 14,366.24. The S&P 500 also fell, dropping, 0.02% to 4,603.60.